Bruno Alicke

3.3k total citations · 1 hit paper
32 papers, 2.3k citations indexed

About

Bruno Alicke is a scholar working on Molecular Biology, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Bruno Alicke has authored 32 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Molecular Biology, 7 papers in Oncology and 5 papers in Pathology and Forensic Medicine. Recurrent topics in Bruno Alicke's work include Hedgehog Signaling Pathway Studies (6 papers), Glioma Diagnosis and Treatment (3 papers) and PI3K/AKT/mTOR signaling in cancer (3 papers). Bruno Alicke is often cited by papers focused on Hedgehog Signaling Pathway Studies (6 papers), Glioma Diagnosis and Treatment (3 papers) and PI3K/AKT/mTOR signaling in cancer (3 papers). Bruno Alicke collaborates with scholars based in United States, France and Singapore. Bruno Alicke's co-authors include Stephen E. Gould, Frédéric J. de Sauvage, Robert L. Yauch, Gerrit J.P. Dijkgraaf, Thomas Januario, Christopher A. Callahan, Tracy Tang, Zora Modrušan, Charles M. Rudin and Zhengyan Kan and has published in prestigious journals such as Nature, Science and Proceedings of the National Academy of Sciences.

In The Last Decade

Bruno Alicke

31 papers receiving 2.2k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Smoothened Mutation Confers Resistance to a Hedgehog Pathway Inhibitor in Medulloblastoma

2009 670 citations Robert L. Yauch, Gerrit J.P. Dijkgraaf et al. Science profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Bruno Alicke United States	21	1.8k	566	328	259	233	32	2.3k
Barbara Stecca Italy	32	3.2k 1.8×	1.2k 2.2×	516 1.6×	178 0.7×	328 1.4×	65	3.8k
Rémy Pedeux France	27	1.8k 1.0×	661 1.2×	129 0.4×	146 0.6×	78 0.3×	66	2.4k
Christina Dahl Denmark	21	863 0.5×	604 1.1×	167 0.5×	220 0.8×	359 1.5×	34	1.6k
Karl Dykema United States	25	1.3k 0.7×	465 0.8×	220 0.7×	85 0.3×	141 0.6×	41	2.0k
Elizabeth E. Reczek United States	9	2.1k 1.2×	1.2k 2.1×	197 0.6×	122 0.5×	166 0.7×	10	3.2k
Matthieu Lacroix France	18	1.1k 0.6×	516 0.9×	121 0.4×	104 0.4×	83 0.4×	28	2.0k
Sílvia Carvalho Israel	23	1.1k 0.6×	516 0.9×	137 0.4×	50 0.2×	184 0.8×	36	1.8k
Phil F. Cheng Switzerland	29	1.6k 0.9×	1.3k 2.3×	148 0.5×	170 0.7×	177 0.8×	96	2.9k
Sheri L. Holmen United States	28	2.1k 1.2×	784 1.4×	407 1.2×	572 2.2×	156 0.7×	63	3.0k
Ferenc Boldog United States	21	1.8k 1.0×	517 0.9×	500 1.5×	73 0.3×	143 0.6×	36	2.5k

Countries citing papers authored by Bruno Alicke

Since Specialization

Citations

This map shows the geographic impact of Bruno Alicke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bruno Alicke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bruno Alicke more than expected).

Fields of papers citing papers by Bruno Alicke

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bruno Alicke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bruno Alicke. The network helps show where Bruno Alicke may publish in the future.

Co-authorship network of co-authors of Bruno Alicke

This figure shows the co-authorship network connecting the top 25 collaborators of Bruno Alicke. A scholar is included among the top collaborators of Bruno Alicke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bruno Alicke. Bruno Alicke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Salphati, Laurent, Jodie Pang, Bruno Alicke, et al.. (2024). Preclinical characterization of the absorption and disposition of the brain penetrant PI3K/mTOR inhibitor paxalisib and prediction of its pharmacokinetics and efficacy in human. Xenobiotica. 54(2). 64–74. 5 indexed citations

Alicke, Bruno, Eugene Varfolomeev, Alexandra Frommlet, et al.. (2022). IAP antagonist GDC-0917 is more potent than Debio1143 in promoting cell death, c-IAP1 degradation and tumor growth inhibition. Cell Death and Disease. 13(9). 831–831. 3 indexed citations

Forrest, William F., Bruno Alicke, Oleg Mayba, et al.. (2020). Generalized Additive Mixed Modeling of Longitudinal Tumor Growth Reduces Bias and Improves Decision Making in Translational Oncology. Cancer Research. 80(22). 5089–5097. 11 indexed citations

Alicke, Bruno, Klára Tótpál, Jill Schartner, et al.. (2020). Immunization associated with primary tumor growth leads to rejection of commonly used syngeneic tumors upon tumor rechallenge. Journal for ImmunoTherapy of Cancer. 8(2). e000532–e000532. 15 indexed citations

Salphati, Laurent, Sheerin Shahidi-Latham, Kai Barck, et al.. (2014). Distribution of the Phosphatidylinositol 3-Kinase Inhibitors Pictilisib (GDC-0941) and GNE-317 in U87 and GS2 Intracranial Glioblastoma Models—Assessment by Matrix-Assisted Laser Desorption Ionization Imaging. Drug Metabolism and Disposition. 42(7). 1110–1116. 36 indexed citations

Metcalfe, Ciara, Bruno Alicke, Ailey Crow, et al.. (2013). PTEN Loss Mitigates the Response of Medulloblastoma to Hedgehog Pathway Inhibition. Cancer Research. 73(23). 7034–7042. 44 indexed citations

Gong, Inna Y., Wendy A. Teft, Justin Q. Ly, et al.. (2013). Determination of clinically therapeutic endoxifen concentrations based on efficacy from human MCF7 breast cancer xenografts. Breast Cancer Research and Treatment. 139(1). 61–69. 28 indexed citations

Wong, Harvey, Edna F. Choo, Bruno Alicke, et al.. (2012). Antitumor Activity of Targeted and Cytotoxic Agents in Murine Subcutaneous Tumor Models Correlates with Clinical Response. Clinical Cancer Research. 18(14). 3846–3855. 96 indexed citations

Wong, Harvey, Bruno Alicke, Kristina West, et al.. (2011). Pharmacokinetic–Pharmacodynamic Analysis of Vismodegib in Preclinical Models of Mutational and Ligand-Dependent Hedgehog Pathway Activation. Clinical Cancer Research. 17(14). 4682–4692. 96 indexed citations

10.

Chen, Weiwei, Tracy Tang, Jeff Eastham-Anderson, et al.. (2011). Canonical hedgehog signaling augments tumor angiogenesis by induction of VEGF-A in stromal perivascular cells. Proceedings of the National Academy of Sciences. 108(23). 9589–9594. 93 indexed citations

11.

Wong, Harvey, Edna F. Choo, Bruno Alicke, et al.. (2011). Abstract A11: Antitumor activity of targeted and cytotoxic agents in xenograft models correlates with clinical response: A pharmacokinetic-pharmacodynamic analysis.. Molecular Cancer Therapeutics. 10(11_Supplement). A11–A11. 3 indexed citations

12.

Choo, Edna F., Bruno Alicke, Jason Boggs, et al.. (2011). Preclinical assessment of novel BRAF inhibitors: integrating pharmacokinetic-pharmacodynamic modelling in the drug discovery process. Xenobiotica. 41(12). 1076–1087. 5 indexed citations

13.

Dijkgraaf, Gerrit J.P., Bruno Alicke, Lasse Weinmann, et al.. (2010). Small Molecule Inhibition of GDC-0449 Refractory Smoothened Mutants and Downstream Mechanisms of Drug Resistance. Cancer Research. 71(2). 435–444. 293 indexed citations

14.

Yauch, Robert L., Gerrit J.P. Dijkgraaf, Bruno Alicke, et al.. (2009). Smoothened Mutation Confers Resistance to a Hedgehog Pathway Inhibitor in Medulloblastoma. Science. 326(5952). 572–574. 670 indexed citations breakdown →

15.

Varfolomeev, Eugene, Bruno Alicke, J. Michael Elliott, et al.. (2009). X Chromosome-linked Inhibitor of Apoptosis Regulates Cell Death Induction by Proapoptotic Receptor Agonists. Journal of Biological Chemistry. 284(50). 34553–34560. 47 indexed citations

16.

Alicke, Bruno, David R. Light, Kirk Mclean, et al.. (2009). In Vivo Biodistribution, PET Imaging, and Tumor Accumulation of ⁸⁶Y- and ¹¹¹In-Antimindin/RG-1, Engineered Antibody Fragments in LNCaP Tumor–Bearing Nude Mice. Journal of Nuclear Medicine. 50(3). 435–443. 62 indexed citations

17.

Cohen, Frederick, Bruno Alicke, Linda O. Elliott, et al.. (2009). Orally Bioavailable Antagonists of Inhibitor of Apoptosis Proteins Based on an Azabicyclooctane Scaffold. Journal of Medicinal Chemistry. 52(6). 1723–1730. 30 indexed citations

18.

Han, Ying, Sandra L. Biroc, Weiwei Li, et al.. (2006). The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models. Molecular Cancer Therapeutics. 5(9). 2158–2164. 157 indexed citations

19.

Foreman, Pamela K., Bruno Alicke, Imre Kovesdi, et al.. (1998). Adenovirus-Mediated Transduction of Intestinal Cells In Vivo. Human Gene Therapy. 9(9). 1313–1321. 31 indexed citations

20.

Bartolomé, Jorge, Bruno Alicke, & Maria B. Bartolome. (1997). Central administration of morphine inhibits brain and liver ornithine decarboxylase activity in neonatal rats: Involvement of transcription- and non-transcription-dependent mechanisms. European Journal of Pharmacology. 331(2-3). 145–153. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact